Pharmaceutical Drug Development Annual Market Review 2024-2025 Key Shifts And Strategic Priorities For Companies Navigating Evolving Pharma Ecosystem

2025-09-10 09:16:42

(MENAFN- GlobeNewsWire - Nasdaq) The report outlines key market opportunities in the pharmaceutical industry for 2024, focusing on drug development and regulatory trends. It highlights investment opportunities, strategic focus areas for newcomers, leadership insights for large pharma, and partnership prospects for SMEs looking to align with future trends.

Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drug Development Annual Review - 2024" report has been added to ResearchAndMarkets's offering.
This report investigates the year 2024 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
This report gives important, expert insight you won't find in any other source. 21 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines.

This report is required reading for:

Investors that want to understand past trends impacting the biopharmaceutical industry as well as identifying companies to invest in
Companies that are interested in entering the biopharmaceutical space and where best to focus on
Large pharma companies with investment groups or BD teams looking to see which companies lead the industry in the past and how they led
Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities

Reasons to Buy

Insights on how drug development in 2024 may impact future approvals
Insights on how drug approvals in 2024 may impact future drug development and approval trends
Sales and regulatory-based insights into 2024 covering various drugs and companies

Key Topics Covered:
1 Executive Summary
2 2024 Pipeline Development
2.1 Top pipeline therapy areas
2. 2 Pipeline drugs by highest development stage
2.3 Top drugs by molecule type
2.4 Top drugs by target
3 2024 Approvals
3.1 FDA, EMA, Japan regulatory approvals, 2022-2024
3.2 US Fast Track Designation approvals, 2022-2024
3.3 Rare Pediatric disease designation approvals, 2022-2024
4 2024 Sales
4.1 2023 vs 2024 sales
4.2 2023 vs 2024 company market capitalization
5 Key Findings
6 Appendix

Companies Featured

Pfizer
Merck & Co
Novartis AG
Johnson & Johnson
Abbvie
F.Hoffman-La Roche Ltd
Bristol-Myers Squibb Co
Astrazeneca Plc
GSK plc
Bristol Myers-Squibb Co
Sanofi

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN10092025004107003653ID1110043389

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.